Combined CTLA-4 and PD-1 inhibition a single institute in-depth analysis of toxicity and efficacy in patients treated at the Dana-Farber Cancer Institute by Munivenkata Swamy, Preethi
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Combined CTLA-4 and PD-1
inhibition a single institute in-depth
analysis of toxicity and efficacy in
patients treated at the Dana-Farber
Cancer Institute
https://hdl.handle.net/2144/26950
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
Thesis 
 
 
 
 
COMBINED CTLA-4 AND PD-1 INHIBITION IN ADVANCED MELANOMA: A    
SINGLE INSTITUTE IN?DEPTH ANALYSIS OF TOXICITY AND EFFICACY IN 
PATIENTS TREATED AT THE DANA-FARBER CANCER INSTITUTE 
 
 
by 
 
 
 
 
PREETHI MUNIVENKATA SWAMY 
 
B.Pharm., Rajiv Gandhi University of Health Sciences, 2014 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science  
 
2017  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 PREETHI MUNIVENKATA SWAMY 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 ?anice Weinberg, Sc.D. 
 Professor of Biostatistics 
                           Director, Master of Clinical Investigation 
 
 
Second Reader   
 ?atrick A Ott, M.D., Ph.D. 
 Assistant Professor of Medicine 
                           Harvard Medical School 
 
 
Third Reader   
 ?aomi Ko, M.D., M.P.H, A.M. 
 Assistant Professor of Medicine 
 
		 iv 
DEDICATION 
 
I would like to dedicate this work to all Melanoma patients and patients of other systemic 
cancers treated with the check-point inhibitor immunotherapy, especially for those patients, 
who have experienced severe adverse events during the course of the treatment. It is my 
hope that, future cancer patients treated with check-point inhibitor immunotherapy, have 
access to well- established clinical care for management of symptoms which manifest due 
to the immune-related adverse events.  
 
 
 
 
 
 
 
 
 
 
 
 
                                            
 
  
		 v 
 
ACKNOWLEDGMENTS 
I would like extend my heartfelt gratitude to all the people who have supported me in my 
pursuit of the masters of degree and this thesis project.  
 
I would like to first thank, Dr. Patrick Ott for giving me this valuable opportunity to 
collaborate on this project at the Dana-Farber Cancer Institute. Thanks for his continued 
mentorship and clinical expertise in this project, without which this project would have not 
taken form.  
 
I would like to extend my since thanks to Dr. Janice Weinberg, who is my faculty advisor, 
reader of this thesis and a great mentor, for her ever growing support and in believing in 
my abilities to perform my best throughout my journey in this program at Boston 
University.  
 
I would also like to thank my reader, Dr. Naomi Ko for her great insights and assistance in 
the field of oncology. 
 
A special thanks to Dr. Girish Naik for his constant advice and research support in this 
project from the start. He has also read and reviewed several sections of this project.  
 
		 vi 
I wish to express my gratitude to Dr. Susan Fish for being an excellent teacher and advisor 
in building my foundation in the fundamentals of conducting clinical research. I promise 
that I will always remember my learnings from her classes.  
 
I wish to acknowledge Juliana Merhaut for being such an ever-inspiring role-model and 
mentor in building my career path in the field of clinical research. 
 
I would like to bestow my deepest thanks to Stacey Hess Pino. Right from the start of my 
time at Boston University, she has been my strongest source of support and encouragement. 
Her door was always open for assistance and advice. She has given her time and help in 
finding this thesis project, several practicums and in helping me face many challenges in 
completion of this project and the program.   
 
Dr. Thomas Travison has been instrumental in building my skills in biostatistics and for 
pushing me to pursue my dreams and aspirations. Dr. Travison has offered considerable 
academic and career advice which has been phenomenal in shaping my career path.  
 
Last but not the least, I would like to thank my ever supportive parents in all my endeavors, 
this far. I owe all of my education and success to my parent’s guidance and blessings. I am 
also indebted to the support and companionship of my sister, Pooja.  	 	
		 vii 
	
COMBINED CTLA-4 AND PD-1 INHIBITION A SINGLE INSTITUTE IN-     
DEPTH ANALYSIS OF TOXICITY AND EFFICACY IN PATIENTS TREATED 
AT THE DANA-FARBER CANCER INSTITUTE 
 
PREETHI MUNIVENKATA SWAMY 
 
ABSTRACT 
Purpose: The purpose of this study was to compare the rate of grade 3-4 immune related 
adverse events (irAEs) in patients with advanced metastatic melanoma treated with the 
combined anti-CTLA-4 and anti-PD-immune-therapy at the Dana Farber Cancer 
Institute(DFCI), to that of the published rate of grade 3-4 irAEs among patients treated 
with the same combination of check-point therapy in the pivotal phase II and phase III 
trials that led to the FDA approval of the combination regimen. This study also measures 
the tumor response with the Ipi-Nivo combination therapy and overall-survival of patients 
in the study cohort at DFCI.  
 
Methods/Procedures: This is a retrospective cohort study conducted at DFCI during 2014 
to 2016 among stage III/IV melanoma patients treated outside of the clinical trials with the 
Ipi-Nivo combination therapy. Chart review of the electronic medical record(EMR) was 
conducted to abstract the data for this study. irAEs were graded and classified as per the 
NCI-CTCAE v.4.0 guidelines. The comparison of the rate of grade 3 4 toxicity in the 
		 viii 
clinical settings at DFCI and the clinical trials was performed using a one sample 
proportion hypothesis test.  
For efficacy assessment of tumor response, RECIST1.1 criterion was used to ascertain the 
best clinical response. 
 
Results:  During an overall follow-up period of 600 days, 52 patients were treated on 
expanded access protocol (EAP) and commercial Ipi-Nivo combination therapy at DFCI.  
The rate of grade 3-4 immune mediated toxicity for this cohort of patients treated outside 
of clinical trials was 32.6%.   The average rate of grade 3-4 irAEs reported in phase II/III 
clinical trials was approximately 55%. The results from the one-proportion hypothesis test 
[(P-value: 0.002) (95% C.I: 19.14-46.23)], prove that patients in the “real world” clinical 
settings have a different safety profile than patients treated in the clinical trials. The rate of 
grade 3-4 irAEs was found to be lower (19.14% to 46.23%) in the population treated with 
Ipi/Nivo combination therapy at the DFCI, compared to the check-mate clinical trials 
(approximately 55%) 
 
Conclusion:  The results from the study indicate a lower rate of grade 3-4 irAEs in patients 
treated at DFCI, in comparison with the patients treated in the clinical trials for the Ipi-
Nivo combination group. The results support the need for preemptive safety signal 
detection of symptoms of irAEs to improve patient’s safety. However, larger database 
studies are required for the generalizability of this results to a wider patient population 
treated outside of DFCI.	  
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INTRODUCTION 
 	 Melanoma is defined as the malignant neoplasm derived from the cells 
(melanocytes) that gives the skin its pigment, melanin. 1 In the United States , it is estimated 
that, of  the 87,110 new cases of melanoma that will be diagnosed in 2017 , about 52,170 
(59.89%) will be men and 34,940 (40.11%) will be women2. It is also predicted that 9,730 
deaths will occur due to melanoma in 20172,3. The risk factors for developing Melanoma 
increases with age >60 years, among males, phenotypic pre-disposition such as, the 
presence of atypical moles, increased mole count, UV exposure, and skin sensitivity ,  
especially for sun burns4. Although melanoma of the skin originates as cutaneous 
melanoma through the melanocytes, these cells are also present in the eye, ear, heart, 
meninges and the bone5. Melanoma metastasizes through the lymphatic system to the 
regional lymph nodes, lungs, bones, liver and brain1.  
According to the AJCC, the clinical staging of melanoma is presented in Table 1:  
 
Table 1. Clinical staging of Melanoma 
 
STAGE CLINICAL STAGING 
Stage 0 Tis No Mo 
Stage IA T1a No Mo 
Stage IB T1b No Mo 
Stage IB T2a No Mo 
	2 
Stage IIA T2b No Mo 
Stage IIB T3b No Mo 
Stage IIIB T4a No Mo 
Stage IIC T4b No Mo 
Stage III Any T >=N1 Mo 
Stage IV Any T N1-3 M1a-
M1c 
 
T stage indicates the thickness of the primary tumor (table 2), ulceration and mitosis status.  
 
Table 2: Melanoma staging (definition of T stage)  
Primary tumor T Definition  
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor  
Tis Melanoma in-situ 
T1 Melanoma 1.0 mm in thickness  
T2 Melanoma 1.1- 2.0 mm in thickness 
T3 Melanoma 2.1- 4.0 mm in thickness 
T4 Melanoma > 4.0 mm in thickness  
 
T4 is the highest and it indicates greater melanoma thickness. N stage is determined 
by presence/absence of regional lymph nodes and is also affected by the ulceration status 
of the primary melanoma, The N value from N1-N3, where N3 is the highest and indicates 
Distant	metastasis:		
• M0:	No	evidence	of	metastasis	
• M1a:		Skin,	subcutaneous	or	distant	lymph	nodes	
• M1b:		Lung	
• M1c:			All	visceral	sites,	distant	metastasis	
• M1d:			Brain		
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a more distant lymph node spread. M stage classifies the site and region of distant 
metastases. For example, a person who has stage IV M1d melanoma has a tumor size 
ranging anywhere from T1-T4. The M value indicates that  the  tumors have metastasized 
to other parts of the body and the brain6.  
According to Bhatia et al, the 10 year survival rate for patients with metastatic 
melanoma is less than 10%7. The Prognostic factors that influence melanoma outcome and 
survival are site of metastases, clinical stage of malignant melanoma, presence of elevated 
serum lactate dehydrogenase (LDH), older age, male sex, , greater number of metastatic 
sites, duration of disease free-survival period, and hypoalbuminemia7. The presence of a 
BRAFV600 gene mutation, which is present in ca. 50% of all malignant melanomas can have 
an impact on the prognosis of malignant melanoma8. The most common BRAF mutation 
is through the V600E (90%) residues, that is the substitution of glutamic acid with valine 
amino acid residues. These BRAF V600 gene mutations are known to increase the catalytic 
activity of MAPK/ERK (Mitogen activated protein kinases/extracellular signal regulated 
kinases) signaling cascade that have underlying mechanisms for melanoma malignancy9. 
The presence of a BRAF mutation in melanoma has been positively associated with the 
genetic variants of the melanocortin-1 receptor. Thereby, indicating that BRAF gene 
mutations have complex genetic determinants in addition to physiochemical mechanism 
for mutation. The presence of a BRAF V600 mutation is associated with high-risk 
melanoma , early age of onset and shortened survival. Interestingly, BRAFV600 mutation 
is more common among intermittent sun exposure as compared to unexposed or even 
chronically sun-damaged skin, which is also associated with poor prognosis of melanoma8. 
	4 
The treatment regimen and outcome for melanoma depends upon the clinical stage 
at presentation. The site of metastases is a significant predictor for patients with distant 
metastatic stage IV melanoma 4. Systemic chemotherapy, using Dacarbazine, an alkylating 
agent was the only FDA approved agent, before the approval of check-point inhibitor 
immunotherapy. Dacarbazine has proved to show poor response rates among melanoma 
patients with only a partial response rate of 11.2% and a complete response rate of 4.2%, 
among a study of 1390 patients who received only Dacarbazine. Prior to the approval of 
Dacarbazine in 1975, resection through surgery was one of the only sought after systemic 
treatment options for metastatic melanoma. High dose Interleukin-2 (HD IL-2) was 
approved by the FDA in 1998, for the treatment of metastatic melanoma. 600,00-720,00 
IU/kg of IL-2 was administered every 8 hours for 2 cycles which consisted of 5 days each 
with a gap of 10 days between the cycles. Although, patients treated with HD IL-2 reported 
extended survival and durable response rates, the  high rate of multi-organ toxicities and 
bacterial sepsis was a defining limitation for treatment with HD IL-2. The failure of 
cytotoxic chemotherapies to provide more durable responses have led to the development 
of  novel immunotherapeutic agents, which  have proven to be more successful in yielding 
better objective response rates among melanoma patients 7.  
 
Role of Immune system in cancer: 
Immune responses are classified as innate anti-tumor responses and adaptive anti-
tumor responses. Innate anti-tumor responses serve as the first line of defense to protect 
the host cells against DNA replication errors, oxidative stress, inflammation and prevent 
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single and double stranded DNA breaks which potentially trigger malignant transformation 
of host cells.10 Innate anti-tumor responses occur via  NK cells, NKT cells, γδT cells, 
granulocytes , macrophages and interferon producing dendritic cells through complex 
interactions with tumors11. The role of innate and adaptive immunity is depicted in Figure 
1.  
Adaptive anti-tumor responses occur via T and B cells. T cells interact with 
dendritic cells, which act as a bridge between innate and adaptive immune systems. 
Dendritic cells capture and process the dying tumor cells for MHC class I and II 
presentation. As these dendritic cells migrate to the draining lymph nodes they trigger 
antigen specific T and B lymphocytes. Additionally, the presence of the dendritic cells in 
the tumor micro-environment triggers “danger” signals from stressed or necrotic tumor 
cells that cause the release of multiple co-stimulatory molecules and cytokines that further 
initiative the activation of effector T-cell responses. Cytokine secretion and cytolysis are 
the key effector mechanisms utilized by T cells. Nevertheless, it has been observed that, 
persistent activation of the innate and adaptive immune responses promotes tumorigenisis, 
proliferation and metastases. Therefore, further research of the complex immune 
surveillance mechanisms of tumor protective and tumor promoting host mechanisms is 
required  to strategically develop immunotherapeutic targets to combat cancer12.  
	6 
Figure 1: Role of innate and adaptive immunity cancer: 
  
 
 
Role of T-cell mediated Immunotherapy in cancer: 
T-cell mediated immune responses involve a sequential multi-step process: clonal 
selection of antigen-specific cells, activation and proliferation in secondary lymphoid 
tissues, execution of effector functions through cytokines and membrane ligands. A 
plethora of co-stimulatory and co-inhibitory molecules are needed for T-cell activation13. 
These co-stimulatory or co-inhibitory molecules are called as check-points. Cancer cells 
bind to check-points on the T-cells and de-activate them. So, check-point inhibitors are 
drug (antibody molecules) that inhibit cancer cells from de-activating T-cells, thereby 
allowing T-cells to infiltrate cancer cells and stop the tumor from growing14. Inhibitory 
mechanisms such as CTLA-4 (cytotoxic T-Lymphocyte antigen-4) and PD-1 
(Programmed death receptor-1) are required to down modulate T cell responses and to 
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prevent autoimmunity. Murine models have shown that blockade of co-inhibitory 
molecules or enhancement of co-stimulatory molecules boost T-cell responses against 
tumors. CTLA-4 and PD-1 are pivotal immune check-point proteins that are assuring 
immunotherapeutic agents15. Co-stimulatory and inhibitory receptors and ligands are not 
generally overexpressed in the tumor microenvironment. However, inhibitory receptors 
and ligands required for T-cell effector functions are overexpressed on tumor cells , relative 
to normal cells13. Recent breakthroughs in immunotherapy for metastatic melanoma have 
developed antibodies that block the feedback control mechanisms at the soluble membrane 
bound TCR-ligand immune check-points using agonistic antibodies for co-stimulatory 
pathways and antagonistic antibodies for inhibitory pathways. Hence, the primary 
mechanism of immune-therapy for check-point inhibitors is via the receptor-ligand, 
resulting in enhanced endogenous anti-tumor activity.  The classical example of such 
immune check-point inhibitor antibodies are Ipilimumab (Yervoy®, from Bristol-Myers 
Squib) against CTLA-4. A similar antibody that blocks PD-1 receptor is 
Nivolumab(Opdivo®, from Bristol-Myers Squib)13,16.  
 
Mechanism of anti-CTLA-4 and development of Ipilimumab: 
CTLA-4 was discovered in late 1998 and is the first immune-check point inhibitor 
to be targeted therapeutically. T-cell activation is a two-step process: the first step is the 
antigen presentation to the TCR by the MHC molecule on the APC’s. The second step 
requires the interaction of the CD28 receptor on the T cells for the activation of the co-
stimulatory molecules B7-1/CD-80 and B7-2/CD86 on the APC’s. CTLA-4 competes with 
	8 
CD28 as CTLA-4 bind to the B7 co-stimulatory ligands and transmits an inhibitory signal. 
Although CD28 is primarily expressed on T cells, CTLA-4 is expressed only on activated 
T-cells via changes in T-cell expression. CTLA-4 still outcompetes CD28, as it has an 
overall higher affinity to both the B7 ligands5,13. The mechanism by which CTLA-4 activity 
triggers intracellular changes that inhibit T-cell activation has not been thoroughly 
established. The plausible mechanisms for T-cell inhibitory signaling cascade include: 1. 
Association with intracellular phosphates like Src homology2(SH2) and protein 
phosphatase 2A. 2. Blockade of lipid-raft expression and 3. Disruption of micro-cluster 
formation. Additionally, CTLA-4 transmits negative signals via B7 to APC, which causes 
the induction of the enzyme, indolamine 2,3 dioxygenase(IDO). IDO inhibits T-cell 
proliferation as it degrades the protein tryptophan17. Figure 2 depicts the mechanism of T-
cell activation and the role of CTLA-4 in immune-check-point inhibition. 
CTLA-4 is expressed significantly on the two subsets CD4+T cells. The 
physiological mechanism for expression occur through downregulation of helper T-cell 
(Thelp) activity and upregulation of regulatory T-cells(Tregs), resulting in 
immunosuppressive activity13. From this it can be concluded that CTLA-4 blockade results 
in a magnification of immune-response by helper T-cells and a suppression of immune by 
Tregs. CTLA-4 targets the Foxp3 fork transcription factor on the Tregs. Therefore, Foxp3 + 
Tregs  express CTLA-4 for immune suppression and maintenance of immune homeostasis18.  
 
	9 
Figure 2: Mechanism of T-cell activation, role of CTLA-4 and mechanism of 
action13 
 
 
 
The pre-clinical development of CTLA-4 blocking antibody in immunogenic 
melanoma mice cell lines showed up to 80% cure rate, when the anti-CTLA-4 antibody 
was combined with GM-CSF vaccine.  
The development of Ipilimumab as a human IgG1 antibody began in Dr. James 
Allison’s laboratory, due to the pre-clinical success of effecting immune augmentation in 
murine cell lines. In the phase III trials published by Hodi et al., 676 subjects with 
previously treated, unresectable stage III or IV melanoma were enrolled in the study. The 
subjects were randomized in a ratio of 1:3:1 to Ipilimumab alone or Ipilimumab plus gp100 
peptide vaccine or gp100 peptide vaccine alone. During pre-clinical development, various 
mouse models featured that chemotherapy and anti-tumor vaccines are synergistic with 
CTLA-4 blockade. The clinical development of Ipilimumab proceeded by comparison with 
vaccination to support and enhance host anti-tumor responses in less strongly immunogenic 
cancers. 19 A 3mg/kg dose of Ipilimumab was administered once in 3 weeks for a total of 
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4 doses. For tumor response assessment, objective response rate was the end-point. 
Objective response rate is defined as the percentage of tumor size reduction in a given time 
which is determined a priori. The objective response rate was observed as 10.9% (2 
Complete responses(CR), 13 partial responses(PR) and 24 stable disease(SD)) with a 
median overall-survival of 10.1 months. The 1- year and 2-years survival rate was reported 
as 45.6% and 23.5% respectively.  In the Ipilimumab+gp100 peptide arm, the objective 
response rate was 5.7%(1CR,22PR,58SD) with a median overall-survival of 10.0 months. 
The 1- year and 2-years survival rate was reported as 43.6% and 21.6%. In the gp100 
peptide alone arm, the objective response rate was reported as 1.5%(0 CRs, 2 PRs and 13 
SD) with a median overall-survival of 6.4 months. The 1- year and 2-years survival rates 
were 25.3% and 13.7%. The toxicity of the immune-therapy, manifestation as immune 
related adverse events(irAEs) for the Ipilimumab, Ipilimumab+gp100 peptide and gp100 
peptide is reported as: 61.1% with 14.5% of grade III/IV irAEs , 58.2% with 10.2% of 
grade III/IV irAEs and 31.% with 3.0% of grade III/IV irAEs, respectively20.  
Due to the efficacy of Ipilimumab and the promising objective response rates from this 
trial, a subsequent double-blind placebo controlled trial of Ipilimumab+ Dacarbazine, and 
Dacarbazine alone, which was the standard of care at that time, was conducted by Bristol-
Myers Squibb. 502 subjects with untreated metastatic melanoma resulted in an increase the 
median overall-survival from 9.1 months (Dacarbazine alone) to 11.2 months (Ipilimumab 
+ Dacarbazine) and an increase the 3-year survival period from 12.2% (Dacarbazine alone) 
to 20.8%(Ipilimumab + Dacarbazine). The	side-effects	of	treatment	with	check-point	inhibitors	 causes	 the	 activation	 of	 immune	 response	 by	 CTLA-4	 and	 PD-1/PD-L1	
	11 
blockade,	resulting	in	the	inflammation	of	the	normal	tissue	(other	than	the	tumor	cells)	which	are	autoimmune	in	nature,	therefore,	termed	as	immune-related	adverse	events(irAE’s)21	.		
The rate of irAEs associated with the Ipilimumab +Dacarbazine therapy was 
reported as 77.3, compared to 38.2% in the Dacarbazine only group. And the rate of grade 
3 irAEs was 31.6% and grade 4 irAEs was 10.1 in the Ipilimumab +Dacarbazine group. 
While the rate of grade 3 and grade 4 irAEs in the Dacarbazine group was 3.2% and 2.8%, 
respectively.  
However, due to significant improvement in the overall survival rates and efficacy, FDA 
approved Ipilimumab in March 2011, marketed as Yervoy® by Bristol-Myers Squibb22.   
Mechanism of anti-PD-1 and development of Nivolumab:  
In addition to CTLA-4, programmed death (PD-1) receptor is another inhibitory 
receptor expressed on T-cells. Immune suppression involving checkpoint inhibition 
targeting the PD-1 receptor and its ligands, PDL-1 and PDL-2 are favorable 
immunotherapies for improving the survival for metastatic melanoma23.  
The role of PD-1 receptor and its ligands in T-cell activation have not been completely 
understood. PDL-1 is integrally expressed on T-cells, B-cells, macrophages, dendritic cells 
and bone-marrow derived mast cells, wPDL-2 is expressed by induction, only on the 
dendritic cells, macrophages and bone-marrow derived mast cells. On the other hand, the 
expression of PD-1 is induced by activation of the T-cells, B-cells and monocytes. 
Numerous studies on cDNA and mRNA have revealed that B7-1 and PD-L1 act as binding 
partners and have the potential to inhibit T-cell proliferation and cytokine production. 
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Experiments have calculated the equilibrium binding constants to measure the degree of 
association between B7-1 and PD-L1 molecules. The affinity between B7-1 and PD-L1 is 
1.7µM, while the affinity between B7-1 and CD-28 is about 4.0µM and that of CTLA-4 
and B7-1 is only 0.2µM. The affinity between PDL-1 and PD-1 is 0.5µM. It can therefore 
be inferred that the affinity between PD-L1 and B7-1 is unique and intermediate which 
allows B7-1 and PD-L1 to inhibit T-cell proliferation, cytokine production and 
cytotoxicity24.  
PD-L1 is expressed in several human tumors including melanoma. A positive 
regulation of PDL-1 expression in metastatic melanoma occurs via IFNγ and activation of 
T-cells , indicating previous anti-tumor activity. Patients with tumors that express PD-L1+ 
have a higher response to anti-PD-1 therapy25. Nivolumab a fully humanized IGg4 antibody 
targeting the PD-1 receptor has been developed by Bristol-Myers Squibb. Nivolumab was 
produced in mice which contain light and heavy chain immunoglobulins along with 
mutations to prevent the synthesis of murine antibodies. Nivolumab yielded tolerable and 
efficacious results in pre-clinical animal testing with cynomolgus monkeys25.  
Further in the phase III clinical trials, patients with previously untreated stage III/stage IV 
and BRAF negative metastatic melanoma, were randomized in a ratio of 1:1 to receive an 
intravenous infusion of Nivolumab at 3 mg/kg of body weight once in every two weeks, 
plus a Dacarbazine matched placebo every three weeks or to receive 1000mg/per square 
meter of body surface of Dacarbazine once in three weeks, plus a Nivolumab matched 
placebo every two weeks. A total of 518 patients were randomized by stratification based 
on PD-L1 status (positive / negative /intermediate) and stage of metastatic disease. 
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Assessment of efficacy of Nivolumab was performed using the response evaluation criteria 
in solid tumors (RECIST) 1.1. The overall survival rate was at one year 72.9% with 
Nivolumab group and 42.1% in Dacarbazine group. The progression-free survival duration 
was 5.1 months in the Nivolumab group and 2.2 months in the Dacarbazine group. The 
objective response rate in the Nivolumab group was 40.0% compared to the Dacarbazine 
arm of just 13.9%. Nivolumab is able to validate its efficacy and prove that it has lower 
risk of toxicity when compared to the conventional treatment with Dacarbazine. Due to 
which, Nivolumab/Opdivo →has been approved for treatment by the FDA, December 2016, 
for the treatment of metastatic or unresectable melanoma and or with disease progression 
in combination with ipilimumab or BRAF inhibitor, if the tumor is BRAF V600 positive27.  
 
 
Anti-CTLA-4 and anti-PD-1 therapy related toxicity (Immune-related 
adverse events):  
The side-effects of treatment with check-point inhibitors causes the activation of 
immune response by CTLA-4 and PD-1/PD-L1 blockade, resulting in the inflammation of 
the normal tissue (other than the tumor cells) which are autoimmune in nature , therefore, 
termed as immune-related adverse events(irAE’s)28. The frequency and severity of irAE’s 
are influenced on the dose of Ipilimumab / nivolumab and also change when combined 
together or with other check-point inhibitors / therapeutic agents. Data from clinical trials 
indicate that irAEs usually occur during the first three months of therapy29. The mechanism 
for Ipilimumab /nivolumab induced irAE’s have not been thoroughly investigated. The 
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pattern of onset of irAEs is depicted in Figure 3. Although irAE’s can occur at any point 
during treatment with ipilimumab, but occur more frequently during the third and fourth 
dose30.  
Figure 3: Pattern of irAE occurrence29 :  
    
 
 
It has been hypothesized that CTLA-4 is necessary to maintain self-tolerance and 
autoimmunity, by preventing the self-activation of T-cells from blocking the production of 
interleukin-2, which results in the arrest of T-cells at the G-1 phase of the cell-cycle. Hence, 
administration of an anti-CTLA-4 antibody infusion, will compromise the host’s 
autoimmunity and self-tolerance, manifested as irAE’s31.  
 
The most common irAE’s are observed as follows: 
1. Dermatological toxicities: Dermatitis is the most common irAE that occurs within the 
first two doses of treatment with Ipilimumab/Nivolumab. It usually manifests as 
maculopapular rash, erythematous rash and/or pruritus. Rash distributes to the extensor 
surfaces of the limbs and the trunk. The histopathological examination of the skin with rash 
indicates epidermal spongiosis, and perivascular lymphocytic infiltrate with eosinophils. 
The rate of grade 3 or 4 dermatitis is rare and occasionally, require admission to hospital 
for management of irAE’s. It generally does not limit or require the need to discontinue 
Skin	toxicity,	usually	first	to	appear	 GI	toxicity,	usually	after1-3	doses	 Hepatotoxicity,	usually	after	3-4	doses	 Endocrinopathy	
3	weeks	 6	weeks		 8-12	weeks	 12-24weeks	
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irAE’s. Ipilimumab/Nivolumab induced skin-rashes are treated with topical emollients, 
anti-histamines and topical steroids30.  
 
2. Enterocolitis: gastrointestinal irAE’s due to Ipilimumab/Nivolumab are common and 
grade 1 or grade 2 occur in approximately 30% of the patients, while grade 3 and grade 4 
colitis occur in less than 5% of patients. The histopathological examination of the stools of 
patients with malignant melanoma, revealed loose, watery stools with few leukocytes, and 
a rare occurrence of blood. Endoscopic examinations revealed ulceration and mucosal 
alterations in 63% of the patients having enterocolitis. The symptoms of colitis are transient 
and reversible with dose interruption and treatment with steroids, and anti-tumor necrosis 
factor is proven to be helpful, particularly in Ipilimumab related immune-colitis32. Patients 
with grade 3-4 diarrhea require hospitalization, I.V hydration, and treatment with high dose 
steroids. Treatment with Infliximab is more beneficial as it promotes intestinal healing and 
can prevent the use of steroids among patients with moderate or moderately severe 
diarrhea30.  
 
3. Hepatitis: Ipilimumab/Nivolumab related hepatitis is common and generally occurs 
during the treatment with the second dose. Symptoms of hepatitis present as inflammation 
of the hepatocytes with elevated liver enzymes AST, ALT and bilirubin levels. Ipilimumab 
induced hepatitis of grade 2 and above is life-threatening and often requires hospitalization 
and discontinuation of check-point inhibitor treatment.  In the clinical trials that were 
conducted before the FDA approval of Ipilimumab, patients with hepatitis B or C were 
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excluded from the trial. In clinical practice, during Ipilimumab treatment, monitoring and 
minimizing the patient’s intake hepatotoxins is imperative. The results of the serum liver 
tests, are often confounded by liver metastases. Therefore, pathological intervention maybe 
required to differentiate Ipilimumab induced hepatitis to that of liver metastasis to improve 
prognosis. Discontinuation of Ipilimumab will be suggested if the treatment of Ipilimumab-
induced hepatitis requires  high-dose steroids or treatment with mycophenolate mofetil30.  
 
4. Endocrinopathy: Ipilimumab /Nivolumab related Endocrinopathy includes 
hypophysitis/hypopituitarism and hypothyroidism. The mechanism of autoimmune 
/lymphocytic hypophysitis with Ipilimumab is due to suppression of autoimmunity, as 
described above. The incidence of hypophysitis is reported to occur at the rate of 1.8% to 
17% in the clinical trials for Ipilimumab33. In the pivotal phase III trials, about 1.9% of 
patients experienced severe, life-threatening endocrinopathies34. In the pivotal phase III 
trials for Nivolumab, thyroid and pituitary anomalies along with diabetes mellitus was 
observed in 7.3% of patients35.   Autoimmune hypophysitis occurs as neoplastic masses 
that arise in or around the sella turcica, a sphenoid cavity in the human skull that bears the 
pituitary gland. The neoplastic sellar masses cause various neurological and hormonal 
symptoms due to the compression of primarily anterior and occasionally the posterior 
pituitary gland culminating as hypothyroidism and hyponatremia, respectively. The 
management and care of autoimmune hypophysitis requires surgical resection of the 
masses / lympholytic medications36. Laboratory diagnosis for Anti-CTLA-4 / anti-PD-1 
induced autoimmune hypophysitis includes TSH, T3, T4, cortisol, ACTH. Hypophysitis 
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with adrenal insufficiency is often life threatening and requires discontinuation of 
ipilimumab. There may be a permanent need for treatment with high-dose I.V steroids and 
mineralocorticoids as applicable to the differential diagnosis of hypopituitarism based on 
clinical symptoms and MRI findings. Additionally, hormone replacement therapy with 
levothyroxine is initiated for hypothyroidism30.  
 
5. Neurological toxicities(Neuropathy):  is a rare irAE related to Ipilimumab and presents 
with non-specific symptoms of numbness and tingling sensation in the extremities. 
However, in rare occasions of less than 1%, life-threatening neuropathies such as Guillain-
Barre syndrome and myasthenia gravis have previously occurred. Therefore, the severity 
of neuropathy must be assessed with MRI scans for disease or treatment related causes 
prior to treatment initiation with methyl prednisone30.  
 
6. Renal Toxicity(Nephritis): is commonly observed with Nivolumab treatment. The 
common side-effects include asymptomatic elevation of serum creatinine, abnormal kidney 
function tests and decreased volume of urine. Renal toxicity occurs during the 10th week 
of treatment. In the pivotal clinical trial of nivolumab, 1.9% of patients had nephritis and 
only one patient was reported with a grade 3 renal failure. Corticosteroid treatment is 
prescribed for management of renal toxicity35.  
 
6. Other toxicities: Other Ipi/Nivo  related irAE’s include ophthalmic involvement of 
uveitis, hematological abnormalities of thrombocytopenia, neutropenia, red-cell aplasia30.  
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Table 3 summarizes the list of possible irAEs along with its signs and symptoms. 
 
 
 
   Table 3: Summary of possible immune-related adverse events28,35,37:  
 
Although treatment with Ipilimumab /Nivolumab has confirmed an increase in 
median progression-free survival for patients with advanced melanoma, the side effects of 
treatment with Ipilimumab due to the mechanism of CTLA-4 / PD-1 blockade inducts 
immune-related adverse events which could potentially be self-limiting to the treatment 
with Ipilimumab/Nivolumab. The adequate management and treatment algorithms of 
System  irAE Signs and symptoms  
Gastrointestinal  Immune-mediated colitis Diarrhea; bowel perforation, abdominal pain, blood/mucus 
stools 
Hepatic Immune-mediated hepatitis Abnormal liver function tests, elevated AST, ALT, bilirubin, 
nausea and vomiting 
Skin Immune-mediated dermatitis Pruritus, maculopapular rash, skin changes 
Neurologic Immune-mediated neuropathy  Paresthesia, numbness, unilateral/bilateral weakness 
Endocrine Immune-mediated 
Endocrinopathy 
Abnormal thyroid test, weight gain or loss, hypopituitarism( 
hypophysitis),behavioral changes 
Pulmonary Immune-mediated 
pneumonitis  
Chest pain, shortness of breath, radiological changes in lung/ 
alveoli, cough 
Renal Immune-mediated nephritis Elevated serum creatinine, blood urine, decreased urine 
output 
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irAEs which involve close monitoring and administration of high-dose steroids, are an 
essential consideration to achieve a clinical benefit from Ipilimumab/Nivolumab20. Fig 4 
depicts the the general irAE management algorithms in clinical care settings.  
Figure 4: Management algorithms for irAE symptoms 
 
 
 
 
Nivolumab in combination with Ipilimumab:  
Several pre-clinical models and clinical trials have demonstrated that, combining 
Nivolumab (anti-PD-1 therapy) and Ipilimumab (anti-CTLA-4 therapy) will 
synergistically provide a stronger immune check-point blockade. Nivolumab-Ipilimumab 
combination will interfere with and block the T-cell activation process at the T-cell 
Grdae	1
• Patient education	• Monitoring	of	symtoms• Exclude	infection
Grade	2 • Consider	oral	corctiosteroid treatment	if	symtoms	persist	>5	days• Withold	treatment	until	toxicity	has	reduced	to	grade	1,	if	necessary
Grade	3
•Withold	tretament	until	resolution	of	symtoms•Steroids	tapering	over	3-6	weeks•Commence	I.V	corticosteroids(1-2mg/kgmethyl	prednisone)•If	symtoms are	not	resolving	in	48	hrs	,	initiate	immunosuppressants	(Infliximab/mycophenolate	mofetil)•consider	systemic	specific	examinations	(colonoscopy)
Grade	4	 • Permanently discontinue	Immunotherapy
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receptor- tumor interface and at the junction of antigen presenting cell- T-cell interaction, 
respectively38. The higher rate of occurrence and management of irAEs with combination 
check-point inhibitor therapy (Ipilimumab-Nivolumab) is a concern in the clinical settings.  
A phase I, 3+3 dose-escalation study performed by Wolchok et al and team in which 
consecutive cohorts of patients with stage III/ IV metastatic melanoma were divided into 
the concurrent regimen group and the subsequent regimen group. Dosing in the concurrent 
regiment group consisted of I.V administration of Nivolumab and Ipilimumab every three 
weeks for four doses, followed by Nivolumab monotherapy every three weeks for a total 
of four doses. The sequential regimen group, received treatment with only Nivolumab at 
dose of 1mg/kg and 3mg/kg every two weeks for a duration of 48 weeks. Safety assessment 
was performed and graded as per the National Cancer Institute’s common terminology 
criteria for adverse events (NCI-CTCAE). In the concurrent-regimen group, treatment 
related adverse events were observed in 93% of the patients. Serious irAEs of grade 3 to 
grade 4 attributed to the treatment were observed in 53% of patients in the concurrent 
regimen group. In the sequential-regimen group, treatment-related grade 3 to grade 4 irAEs 
were observed in 18% (6of the 33) patients. For most patients, treatment related irAEs were 
treated with corticosteroids. Sixty five percent  of patients in the concurrent regimen group 
showed objective response, whereas, only 20% of patients in sequenced regimen group met 
the objective response as outlined in study protocol39.   
 A randomized double-blind phase II study of Nivolumab-Ipilimumab combination 
and Ipilimumab monotherapy was performed by Postow, et al and team. In this study, 
patients were randomized in a 2:1 ratio to the combination arm or to receive Ipilimumab 
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monotherapy. Randomization was stratified based on BFAF V600 mutation status. Dosing 
schedule was divided into two phases, the induction phase and maintenance phase. In the 
induction phase, a total of 4 doses of each, I.V Nivolumab of 1mg/kg of body weight for 
60 minutes was administrated once every three weeks; followed by a 30-minute interval, 
continued by the administration of I.V 3mg/kg of body weight of Ipilimumab for 90 
minutes. In the maintenance phase, only I.V 3mg/kg of body weight of Nivolumab was 
administered for 60 minutes once every two weeks. In the control arm, the same dosing 
schedule was followed in the induction and maintenance phases for Ipilimumab only along 
with a Nivolumab-matched placebo. Response to treatment was evaluated as per RECIST 
1.1 criteria at 12 weeks after start of study treatment, every 6 weeks after the first 
assessment for one year, and every 12 weeks until disease progression or treatment 
discontinuation. For the BRAF wild type tumors, a confirmed objective response rate of 
61% was observed in the combination group and 11% in the Ipilimumab monotherapy 
group. 22% of patients in combination group showed complete response, with complete 
tumor reduction in the combination group and there was no significant complete response 
reported in the monotherapy arm. In the BRAF V600 positive mutation group, the objective 
response rate was reported as 52 % and 22% of these patients were reported to show a 
complete response in the combination group. No significant percentage of patients were 
reported to show an objective response to the Ipilimumab monotherapy in the BRAF 
positive mutation group.  
Drug related adverse events due to the immune-therapy were distinctively 
monitored and managed as per clinical guidelines. The rate of grade 3 and/or grade 4 
	22 
immune related adverse events in the combination arm (54%) was more than double the 
rate in the Ipilimumab monotherapy (24%). The most common immune-related adverse 
event was colitis (about 17%) in the combination group and diarrhea (11%) followed by 
colitis (7%) was reported in the monotherapy arm. About 45% of the patients in the 
combination treatment group discontinued due to treatment related immune- adverse 
events. About 37% of patients in the Ipilimumab monotherapy group were counted to have 
disease progression. 3 of the 25 deaths in the combination group occurred due to treatment 
related immune-adverse events 40. Table 4 summarizes the findings from the checkmate 
069 and 067 trials. 
A double blind phase III randomized study (checkmate 067) was performed by 
Larkin et al and team to assess the progression free survival and overall survival, in addition 
to evaluating safety of the combination therapy versus the monotherapy. Patients were 
randomized in a 1:1:1 ratio into three study arms: the first arm received 3mg/kg of body 
weight of I.V Nivolumab plus ipilimumab matched placebo every two weeks. The second 
arm consisted of 1mg/kg of Nivolumab once every three weeks and 3mg/kg of ipilimumab 
once every 3 weeks for four doses, followed by maintenance dose of 3mg/kg of Nivolumab 
every two weeks. Patients in the third arm of the study received 3mg/kg of Ipilimumab 
once every three weeks for a total four doses, plus Nivolumab matched placebo. Median 
progression free survival was measured as the primary study end point, the combination 
arm reported a significant 11.5 months whereas the Nivolumab monotherapy reported a 
6.9 months and the Ipilimumab group reported a low duration of only 2.9 months. Safety 
assessment was performed and treatment related adverse events were monitored. The 
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combination treatment group reported 95.5% of adverse events, while the Nivolumab only 
group had 82.1% of adverse events and the ipilimumab only group reported about 86.2% 
of adverse events. Discontinuation of study treatment due to the adverse events were highly 
reported in the combination group in 36.4% of patients. For the management of the adverse 
events immune- modulating agents and steroids were prescribed for 83.4% of the patients 
.  
From all of the above listed studies it can be concluded that higher clinical response 
and progression free survival rates are observed with combination of Ipilimumab-
Nivolumab compared to Nivolumab monotherapy or Ipilimumab monotherapy. 
Ipilimumab arrests CTLA-4 activation which improves overall survival in melanoma 
patients and Nivolumab blocks PD-1 activation and results in more durable objective 
response rates. This synergistic action of Ipilimumab –Nivolumab provides a complete 
check-point blockade of T-cell mediated immune system, thereby improving the clinical 
outcome and efficacy of the treatment 41. Conversely, the incidence of treatment-related 
adverse events of grade 3 to 4 is higher in the combination therapy.  
Table 4: summary of results from the check-mate 069 and 067 trials:  
     Checkmate-069   Checkmate-067  
Response Ipilimumab 
(N=47)  
Ipi/Nivo 
(N=95)  
Ipilimumab 
(N=315)  
Nivolumab 
(N=316)  
Ipi/Nivo 
(N=314)  
Efficacy       
Response Rate (%)  11	 61	 19	 44	 58	 
Complete Response 
(%)  
0	 22	 2	 9	 12	 
Median PFS 
(months)  
4.4	 NR	 2.9	 6.9	 11.5	 
Toxicity (%)       
Drug Related AE  93	 91	 86	 82	 96	 
Grade 3-4  24	 54	 27	 16	 55	 
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Selected AEs of 
interest (all grades)  
     
Colitis  13	 23	 12	 1	 12	 
Hypophysitis  6	 12	 4	 1	 8	 
Endocrinopathy 
(Hypothyroidism)  
15	 16	 4	 9	 15	 
Hepatic  4	 28	 7	 6	 30	 
Pneumonitis  4	 11	 2	 1	 6	 
Dermatitis 59	 71	 54	 42	 59	 
AE leading to 
discontinuation  
17	 47	 15	 8	 36	 																																																												
Study Rationale 
Previous studies discussed in the earlier sections have proven the clinical efficacy 
of treatment with check-point inhibitors in achieving durable objective response rates and 
increasing the overall-survival of patients with metastatic melanoma20,39–42. The wide range 
of treatment related- adverse events which are observed is a clinical concern for effective 
management of the toxic effects. Management of adverse events and constant monitoring 
for safety signals is imperative when patients are treated with immune check-point 
inhibitors43. The use of anti- CTLA-4 and anti-PD-1 antibodies leads to an infiltration of 
highly-activated CD4 and CD8 T- cells which in turn increases the production of activated 
cytokines even in normal tissues leading to inflammation. As discussed previously, 
immune-related adverse events are characteristic in their occurrence which are specific to 
the use of immune-modulating antibodies such as check-point inhibitors15. A Danish 
database study on metastatic melanoma reported  that 55 % of patients in  “real world” 
clinical settings, with metastatic melanoma did not meet the inclusion criteria specified in 
the phase III clinical trials that led to the approval of Ipilimumab and Nivolumab by the 
European Medicines Agency (EMA)44. The pivotal trial (checkmate 067 trial) that led to 
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the FDA approval of the Ipilimumab-Nivolumab combination regimen,  excluded patients 
with active brain metastasis, subjects with active or suspected autoimmune diseases, 
patients with comorbidities such as type I diabetes mellitus,  residual hypothyroidism 
requiring hormone replacement therapy, patients on systemic therapy for psoriasis, subjects 
who have a current prescription of corticosteroids or other immunosuppressive 
medications, or patients who have undergone a prior treatment with drugs targeting the T-
cell co-stimulation pathway or immune check point inhibitors45. In this study, we 
hypothesize that the population of patients with metastatic melanoma in real world clinical 
setting patients are not a true representation of subjects enrolled in the phase III clinical 
trials (checkmate 067 trial). Therefore, patients treated outside of the clinical trials may 
have a different safety profile compared to published data in the Phase III clinical trials, 
when treated with Ipilimumab and Nivolumab. The rationale for this is due to the fact that 
many patients who are treated outside of clinical trial protocols have more comorbidities 
including pre-existing autoimmune conditions and would not have been enrolled in clinical 
trials leading to the FDA approval of these drugs. Secondly, melanoma patients with brain 
metastases were not  part of the clinical trials and analyzing the clinical efficacy of the 
combination regimen in melanoma patients with intracranial metastatic disease could 
provide a first insight of activity in this population, which is a major clinical need.  
 
Purpose of the study:  
The purpose of this study is to evaluate the clinical course for melanoma patients 
presenting with grade 3 to 4 immune-related adverse events, attributed to the combination 
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treatment with Ipilimumab-Nivolumab. Additionally, the study assesses the toxicity 
(incidence of immune-related adverse events) in the real world clinical settings and its 
clinical implications on the efficacy and management guidelines to optimize the use of 
immune check-point blockade antibodies, as a treatment in unresectable / metastatic stage 
III/ IV melanoma.  
 
Primary study Question 
Is the rate of grade 3 or 4 immune related adverse events associated with 
combination immunotherapy (Ipilimumab-Nivolumab) treatment for metastatic / 
unresectable stage III/ IV melanoma at the Dana-Farber Cancer Institute (real world 
clinical settings) different from the rate observed in the checkmate 069 and 067 clinical 
trial that led to the FDA approval of the combination therapy?  
 
Primary objective:  
1. To measure and evaluate the rate of grade 3 or grade 4 immune-related adverse events, 
following treatment with combined Ipilimumab-Nivolumab, experienced by patients with 
metastatic melanoma at the Dana-Farber Cancer Institute.  
 
Secondary objective:   
2a) To measure the overall response rate and overall survival for all patients.  
2b) To measure the frequency of immune suppressive treatments including steroids and 
infliximab as well as hormone replacement therapy utilized for resolution of irAE.																	
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METHODS 
Study design: 
This is a retrospective cohort study conducted at the Dana-Farber Cancer Institute 
(DFCI) from 2014 to 2016. Subjects were identified through the EMR (electronic medical 
record) at DFCI.  
All adults (≥ 18 years) diagnosed with stage III or stage IV unresectable or metastatic 
melanoma as per AJCC staging system, were treated via the expanded access program 
(EAP) or commercially available Nivolumab combined with Ipilimumab.  
 
Dosing regimen: 
Part I: I.V Nivolumab 1 mg/kg for over 60 minutes + I.V Ipilimumab 3 mg/kg for 
about 90 minutes, every 3 weeks and total duration of 4 cycles each.   
Part II: I.V Nivolumab 3 mg/kg for 60 minutes, every two weeks for a maximum period of 
48 weeks, until progression of disease or unacceptable toxicity occurs resulting in 
termination of treatment.  Figure 5 describes the the study population and dosing regimen.  
 
Study Population: 
Inclusion criteria: 
1. All adults (≥ 18 years) diagnosed with stage III or stage IV unresectable or metastatic 
melanoma as per AJCC staging system. 
2. Patients receiving treatment on the EAP and commercial use of Nivolumab+ Ipilimumab 
combination therapy.   
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3. ECOG (Eastern Cooperative Oncology Group) performance status of < 2.  
4. Subjects may have undergone prior treatment with other systemic treatment for localized 
or metastatic disease, except anti- CTLA-4 and anti-PD-1.  
5. Subjects with brain metastases are included provided that their brain lesions have been 
treated and there is no evidence of progression seen in MRI scans. 
 
Exclusion criteria:  
1. Prior treatment with either CTLA-4 or PD-1 inhibitors.  
2. Subjects on treatment with high dose systemic corticosteroids(>10mg/day).  
 
Figure 5: Study schema:  
 
 
Population	
• Unresectable	or	Metatstic	melanoma	(stage III/IV)• Subjects	may	nothave	had	prior	treatment	with	anti-CTLA-4/	anti	PD-1/PD-L1
Dosing
• Part	I(Induction	phase):	Nivolumab	1mg/Kg IV+3mg/kg	Ipilumab	every	3	weeks	X	4	cycles• Part	II(Maintainencephase):	3mg/kg of	Nivolumab	every	2	weeks
Assessment
• Treat	for	a	maximum	of	48	weeks	in	Part II	until	progression	or	unacceptable	toxicity	•Tumor response	assessment	for	best	over-all	response• Safety	monitoring	for	irAEs	
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 Procedure for data curation and recording of irAE’s:  
Chart review of patient profiles undergoing treatment with combination therapy on 
EAP and commercial Ipi-Nivo from 2014-2016 was performed on EPIC by reviewing the 
patient’s research tab that provides information on treatment start and end dates, study 
visits, dose cycles along with the current status in response to the treatment. Further, the 
progress notes were reviewed to monitor and record irAE’s and investigator/clinician 
reviews regarding patient safety and the clinical presentation of irAE’s. Subsequently, 
progress notes and comments were thoroughly reviewed to ensure that the symptoms are 
persistent within the treatment window and if they were believed to be related to the study 
treatment. The procedure for data curation from the EMR to RedCap database is outlined 
in Figure 6, below. All curated data from EPIC was entered into the RedCap (Research 
electronic data capture) research database. 
Figure 6: Schematic representation of data curation of irAEs from EPIC to 
RedCap:  
 
• Research	Status:Active• Receivedtreatment	with	Ipi/Nivo
Chart	Review
• demographic• cancer	staging• laboratory	data	
Progress	notes
• AE	log• AE	related	to	Ipi/Nivo	• AE	within	treatment	window
clinical	visit	log
• NCI-CTCAE	grade	• treatment	• resolution/ongoing
Record	irAE	information
• clincal	response• survival• follow-up
Record	tumor	response	informatioon			
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          Reporting of adverse events and NCI-CTCAE grading system:  
The National cancer institute publishes a grading system which describes the 
severity of the Adverse event. The NCI-CTCAE grading system is represented in Table 5. 
46  All irAEs were graded as per the NCI-CTCAE grading system and reported in the EMR. 
The grade of irAE indicates the nature and severity of the adverse event. Usually grade 3-
4 irAEs are serious and require medical attention and clinical interventions.  
 
Table 5: NCI-CTCAE grading criteria 
 
 
            Efficacy data curation and method of assessment:  
Efficacy data from EPIC were also curated, to assess tumor response to treatment 
by investigators based upon radiological scans at baseline, and every 8 weeks thereafter. 
GRADE                                                  SEVERITY 
Grade 1: Mild, asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.    
Grade 2: Moderate, minimal , local or noninvasive intervention indicated. 
Grade 3: Severe/ medically significant, often requiring hospitalization or prolongation of 
hospitalization. 
  
Grade 4: Life-threatening consequences or disabling AE, urgent intervention indicated 
Grade 5: Death related to AE 
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These responses are recorded in the study visit logs and progress notes. Tumor responses 
were classified as complete response(CR), partial response(PR), stable disease(SD) or 
progressive disease (PD) as per RECIST 1.1 criteria for tumor assessment is listed in below 
in appendix 2.  
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STATISTICAL ANALYSIS 
 
Medical records were reviewed for all the patients in the study cohort to obtain 
information on:  
1. Baseline demographic data and disease characteristics: 
 Descriptive analysis were performed on demographic parameters such as age, sex, 
LDH levels at baseline and prior to administration of each cycle of therapy, BRAF mutation 
status, AJCC melanoma staging at baseline, site / region of metastasis, number of Ipi-Nivo 
combination doses and number of Nivolumab monotherapy doses.  
2. Safety assessments: 
For the primary end-point, safety data were obtained from EPIC as described above. 
All the irAEs experienced by the 52 patients were individually classified, graded and 
reported as mentioned above.  To evaluate the primary study objective, a two sided, one 
proportion hypothesis test was used. The proportion (%) of grades 3-4 irAEs experienced 
among all the 52 patients were collectively computed and used as the observed proportion. 
As per the Larkin et al , checkmate 067 trial, the rate of grade 3-4 immune-related toxicity 
due to treatment with Ipi-Nivo is reported as 55%41. The phase II study (checkmate 069) 
comparing the Ipi-Nivo combination therapy versus treatment with Ipilimumab alone in 
patients with untreated melanoma reported the rate of grade 3-4 irAEs 54%40. For objective 
2(b), descriptive statistics was compiled to assess the total number of patients who received 
corticosteroids, other immunosuppressive treatments and hormone replacement therapy for 
clinical management of irAEs.  
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3. Efficacy assessments 
Objective 2(a) was evaluated using the RECIST1.1 criteria (table). Overall survival 
(OS ) is a valid clinical trial end-point which measures clinical benefit 47. To measure OS 
in this study, time in months is computed from the start of study treatment up to death due 
to any cause (disease related / non-disease related). Survival analysis was plotted on a 
Kaplan-Meier survival curve to estimate the probability of survival at intervals over a given 
length of time48.  Any subject that was lost to follow up was censored at the last follow-up 
date and for all the subject who were alive at the of the study , were censored at the end 
date of the study. The best objective response (BOR) was measured by determining the 
most beneficial responses recorded based on RECIST1.1 criteria for tumor assessment in 
response to the treatment. BOR assessment was designated if the specific response (CR, 
PR or SD) was observed in  consecutive assessments for ≥ 4 weeks. The overall response 
rate is obtained by the proportion (%) of patients with tumor size reduction, resulting in 
either a PR or CR. Disease control rate was obtained by the proportion (%) of patients with 
tumor size reduction (PR or CR) or stable disease (SD).  
All statistical analysis was done using R.4.0 statistical environment. All results 
were considered statistically significant if the null hypothesis could be rejected at alpha = 
0.05. 
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RESULTS 
 
Patients: 
The total study population consisted of 52 patients. The demographic and disease 
characteristics are reported in Table 6. The mean age of the population was 58 years. 
Majority of patients, (94.23%) had stage IV melanoma, at baseline, as per AJCC staging.  
73.07% and 67.30% of patients were reported with M1a (metastasis to skin, sub-cutaneous 
or distant lymph nodes) and M1b (metastasis to lung). There were 8 patients within the 
study cohort with treated brain metastases.  About 38.46% of patients were BRAF V600E 
mutation positive. The mean LDH level prior to the start of treatment was reported as 
229.10 units, with a minimum of 83 units and a maximum of 1293 units.  
Table 6: Demographic and disease characteristic 
    Patients in the study cohort (N=52) 
Male (n [%])                                                                                 
28[53.84] 
Age, years(Median[min-max]) 57[28-84] 
BRAF V600 mutation (n[%])                                                                                 
20[38.46] 
NRAS mutation (n[%]) 8[15.38] 
Stage IV disease (n[%])                                                                                 
49[94.23] 
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55.77% of patients received all four cycles of Ipi-Nivo treatment, and 60% [31 out of the 
52] of patients continued treatment with nivo-mono; with a mean number of doses per 
patient being 9.8 doses of nivo-mono (Table 7). 
Table 7: Number of doses of Ipi/Nivo:  
Total 
count 
(N) 
Min Maximum   Mean St Dev Percentile  
0.05 0.10 0.25 0.50 
Median 
0.90 0.95 
52 1.00 4.00 3.08 1.17 1.00 1.00 2.00 4.00 4.00 4.00 
LDH prior to first 
dose(Median[min-max]) 
178[82-1293] 
 
Follow up (days)  
(Median[min-max]) 
403.5[20-600] 
Metastases sites (n [%]): 
Lymph	node	
Lung	
Soft	Tissue	
Liver	
Bone	
Brain		
	
	
	
 
 
 
  
38[73.07] 
35[67.30] 
28[53.85] 
19[36.53] 
13[25.0] 
 8[15.38] 
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Safety: 
The overall rate of all irAE’s related to Ipi-Nivo combination therapy was 94.12%. 
The rate of grade 3 irAEs was 31% of the rate of grade 4 irAEs was 2.0%. (Table 8) 
describes the proportions of individual irAEs experienced by this population. The most 
commonly occurring irAE due the treatment was Dermatitis in 32 (61.5%) of 52 patients 
and Endocrinopathy reported in 26(50%) of 52 patients. The rate of grade 3 or 4 
enterocolitis 50% and the rate of grade 3 or 4 hepatitis was 30.43%.  “Other” AEs include 
non-classified adverse events that are possibly related to the Ipi-Nivo combination, such 
as, fatigue, headache, pancreatitis resulting in serum amylase and lipase elevation or 
arthralgia.  
Table 8: Rate of irAEs: 
  
irAE(N=52)               Overall  
                N(%) 
        Grade ≥ 3-4 
          n(%) 
Any treatment related  irAE               48(92.3)          17 (32.6) 
Hepatitis                23 (44.2)           7 (30.4) 
Enterocolitis               22 (42.3)           11(50.0) 
Endocrinopathy               26 ( 50.0)            24 (92.3) 
Hypophysitis               10 (19.2)            2 (20.0) 
Dermatitis               32 (61.5)                __ 
Nephritis                 2 (3.8)            1 (50.0) 
Pneumonitis               3 (5.7)            1 (33.3) 
Other                16 (30.7)           3 (18.7) 
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Table 9 depicts the percentage of topical agents, corticosteroids, immune-
modulating agents, hormone-replacement therapy and immunosuppressant (infliximab) 
that were indicated for the treatment of irAEs.  64% (14 of 22) of patients with enterocolitis 
received treatment with corticosteroids and 27 % (6 of 22) of patients with enterocolitis 
received Infliximab. For the treatment of Endocrinopathy, 46% (12 out of 26) of patients 
received hormone-replacement therapy. 62.5% (20 of 32) patients with dermatitis received 
topical agents to treat pruritus and rash. Across all irAEs, 23% (12 of 52) patients withheld 
combination therapy until resolution of symptoms. And 11.5% (6 of 52) patients 
discontinued combination therapy due to severity of the irAEs.  
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Table 9: Treatment for irAE 
 
irAE (N) RESOLUTION (Treatment for irAE) 
 
Cortico-
steroid 
(%) 
Topical 
agents 
(%) 
Hormone 
replacement 
agents (%) 
Immune-
modulating 
agents (%) 
Infliximab 
(%) 
Withheld 
treatment 
(%) 
Discon-
tinued 
treatment 
(%) 
Other 
Enterocolitis 
(22) 
14 
(64%)    6 (2.7%) 6 (2.7%) 1 (4.5%) 3 (14%) 
Hepatitis 
(23) 9 (39%)   2 (8.7%) 1 (4.3%) 1 (4.3%) 1 (4.3%) 
1 
(4.3%) 
Neuropathy 
(2)        
2 
(100%) 
Endocrino-
pathy (26) 
1 
(3.8%)  12 (46%)     
3 
(11.5%) 
Hypophysitis 
(10) 6 (60%)      1 (10%) 1 (10%) 
Nephritis (2) 1 (50%)      1 (10%) 1 (10%) 
Pneumonitis 
(3) 
2 
(66.7%)     2 (66.7%) 1 (33.4%)  
Dermatitis 
(32) 
4 
(12.5%) 
20 
(62.5%)    1 (3.1%) 1 (3.1%) 
3 
(9.3%) 
irAE other 
(16) 
3 
(18.7%)     2 (12.5%)  
1 
(6.2%) 
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To compare the rate of grade 3-4 irAEs in the DFCI population (32.6%) to that of 
the published rate in the phase II and III clinical trials (54.5%), the one sample proportion 
test was used. The results of the one-proportion test are reported in (Table 10). The 
significance level was calculated using the z-test. The rate of grade 3-4 irAEs in the DFCI 
population (alternative hypothesis) was significantly lower than the rate reported in the 
published trials (null hypothesis). The significance level (P-value) was reported as 0.002.  
Since the observed P value is lower than 0.05, the study hypothesis was accepted to be true 
and hence the results indicate that the patients treated at DFCI had a different safety profile 
with the Ipi-Nivo therapy than patients treated on the pivotal trials 49. The 95% confidence 
interval (C.I) of the observed proportion was 19.14-46.23. Since the C.I provides a range 
of values around the observed proportion, the effect size of toxicity (rate of irAEs) can be 
inferred from the result. Therefore, the magnitude of the rate of grade 3 – 4 irAEs (toxicity) 
may be clinically relevant50. Although the rate of toxicity observed at DFCI is not greater 
than the published rate, the rate of grade 3-4 toxicity was found to range from 19.14% to 
46.23% . 
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Table 10: Hypothesis testing: 
HA: Observed proportion grade 3-4 irAEs (%) 
 
      32.6% 
Ho: Published proportion of grade 3-4 
irAEs(%) 
       55% 
z- value                                                                                          -3.09 
Significance level (p value)        0.002 
95% C.I       19.14-46.23 
 
Efficacy: 
As per (Figure 7), a majority of the investigator confirmed best clinical responses 
was observed to be a partial response (PR) among 26 (50%) of 52 of patients. Three patients 
exhibited a complete response. The rate of stable disease (SD) was 11.5%. Progression of 
disease was observed in 32.7% of patients. The overall response (PR+CR) was calculated 
as 53.84%. The disease control rate was obtained by adding the response rates of the 
(PR+CR+SD) =67.3%. Table 11 depicts the tumor response assessment results for this 
study cohort.  
Table 11: Tumor response assessment:  
Best Response Counts / frequency (n[%]) 
Partial response (PR) 26[50.0%] 
Progressive disease (PD) 17[32.7%] 
Stable disease (SD) 6[11.5%] 
Complete response (CR) 3[5.8%] 
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Figure 7: Tumor response Assessment:  
 
 
Survival:  
 
Figure 8 depicts the Kaplan-Meir(KM) survival curve for the study cohort.  
The median overall survival for this cohort was not reached. 8 deaths were reported during 
a maximum follow-up period of 600 days and all the 8 patients reported to have progressive 
disease at the time of last follow-up.  
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Figure 8:  Overall- survival 
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DISCUSSION 
In the DFCI study cohort the percentage of overall treatment related irAEs was 
observed in 48(94.12%) of 52 patients and the rate of grade 3- 4 irAEs was observed in 17 
(32.6%) of 52 patients. In the Checkmate 067 phase II trial, the overall percentage of 
treatment related irAEs was more frequent in the Ipilimumab+ Nivolumab (83 [88%] of 
the 94 patients) combination group than in the Ipilimumab mono group.  The rate of grade 
3-4 irAEs was reported in 51(54%) of 94 patients51. In the phase III trial, the overall-rate 
of treatment related irAE occurred in 95.5% of the patients and the incidence of grade 3-4 
irAEs was 55%52. In  the Phase II checkmate 069 study, the most frequently occurring irAE 
for patients in the combination  group, was immune-mediated colitis , which occurred at 
the rate of 12%. Followed by elevated levels of alanine aminotransferase in at the rate of 
11% 51. In the phase III study, the commonly reported irAEs were, diarrhea (44.1%), 
fatigue (35.1%) and pruritus (33.2%)52. In the DFCI cohort , dermatitis(32%) and 
Endocrinopathy(26%) were the most commonly observed irAE that occurred at the rate of 
the discontinuation rate in the checkmate 069 trial was 49% and 36.4% in checkmate 067 
trial. to study drug related effects51. During the follow up period of the current study, 5% 
of patients discontinued study treatment due to treatment related irAEs, and 11% of patients 
withheld treatment until resolution of symptoms, which is also a significantly lower rate 
compared to the checkmate 069 and 067 trials. 
In this study cohort, 50% of patients had a partial response(PR) as the best clinical 
response and only 3 patients showed a complete response. Investigator confirmed best 
clinical responses displayed that 36 (11.5%) of 314 patients showed a complete response 
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and 46.2% (145 of the 314 patients) reported a partial response in the phase III trial52. Over 
a follow up period of 600 days, 8 patients died. In the check-mate Phase II trial the median 
overall survival was not reached in either of the treatment groups51.   
Although the follow up period (600 days) for this study was not as long as the follow up 
for the pivotal phase II and phase III trials. This study represents the data from the real 
world clinical settings of patients treated outside of the interventional protocols.  
 
We hypothesized that patients treated in the real word clinical DFCI will have a 
higher rate of toxicity compared to patients enrolled on clinical trials.  However, the result 
from the hypothesis test (p=0.002), indicates that, the DFCI cohort had a lower rate of 
toxicity compared to the subjects treated in the check-mate 067 and 069 trials. The 95% 
C.I of 19.14 to 46.23 does not include the published rate from the check-mate trial of 54%. 
This implies that the rate of grade 3-4 toxicity is lower in DFCI cohort. Nonetheless, 
patients treated at the DFCI were a less restricted population than the subjects that were 
treated in the check-mate trials. Since the cohort at DFCI included patients with other 
autoimmune diseases we expected that this cohort may have a higher rate of toxicity than 
the pivotal phase II/phase III trials. These results may reflect strict adherence to adverse 
event monitoring and intervention guidelines in the patients treated at the Dana-Farber 
Cancer Institute. In addition, the results also suggest that preemptive adverse event signal 
detection in the clinical settings may have worsening of adverse events to more serious 
advents of higher grade of toxicity. For example, early detection of diarrhea onset could 
prevent the worsening of diarrhea to a severe grade 3-4 immune-mediated colitis. The 
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practice of collecting a detailed medical history in the clinical settings at DFCI during 
baseline assessment could have contributed positively in establish personalized immune-
mediated adverse event monitoring guidelines, and increase patient and clinician awareness 
for irAEs. Some other plausible causes for the lower rate of grade 3-4 irAEs observed at 
DFCI could be due to the reason that subjects in the check-mate clinical trials were 
followed more closely with stringent reporting of irAEs as per protocol guidelines, than 
patients in the real-world clinical settings. Underreport ability of irAEs in patients treated 
outside of clinical trial protocols could be another cause for lower rate observed in this 
cohort. Such as, lack of appropriately documentation in the electronic medical records by 
study nurses; or perhaps the patients visited other clinics to sought treatment for the irAEs 
and some patients were lost to follow-up. The results of this study also inform clinicians 
and other health care professionals that by adhering to established adverse event 
monitoring guidelines, safety signal detection the use of the Ipi/Nivo combination therapy 
could be relatively safe across clinical settings.  
 
Potential biases: 
The plausible causes for the lower rate of irAEs observed in this cohort treated at 
DFCI, compared to the study cohort treated in the phase II/ III trials could be open to 
several interpretations. Tumor response assessment of stable disease could be due to the 
inherent natural course of the disease and may not reflect a therapeutic benefit. After 
treatment with Ipi-Nivo combination, some patients in this cohort received treatment with 
other anti-PD-1 inhibitors such as pembrolizumab or BRAF inhibitors instead of nivo 
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mono and therefore there could be some bias in interpreting the overall survival rate among 
these patients. The etiology of the immune –related adverse events could occur due to other 
existing concomitant illnesses or medications and therefore, confound the ability to 
establish a causality for treatment related irAEs53.  
Holding treatment until the resolution of irAEs or continuing treatment with the use 
steroids to lower the severity of irAEs could further disproportion the assessment of 
magnitude of toxicity related to the treatment.  
Strengths: 
To the best of our knowledge, this is the first study to compare the occurrence of 
the rate of grade 3-4 irAEs in the real world clinical settings of patients treated with the 
Ipi-Nivo combination therapy at The Dana-Farber Cancer Institute to that of the check-
mate clinical trials that led to the FDA approval of the combination therapy. This is also 
the first study to include a hypothesis test (one-sample proportion test) to compare the rate 
of grade 3-4 toxicity between the clinical settings and the pivotal clinical trials. The 
strength of this study also lies in completeness of the all the data points for the entire cohort 
of 52 patients. Hence all the 52 patients were included in the final statistical analysis for 
the primary and secondary objectives. In addition, the availability of additional clinical, 
laboratory and imagining scans in the EMR at DFCI enabled the researches and the 
clinicians to determine the tumor response and analyze other valuable information such as 
resolution parameters and medications prescribed to resolve to the irAEs, which is an 
important tool in assessing the management guidelines followed in the clinical settings.   
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Limitations: 
This study has several limitations. The first two limitations are within the study 
design itself. The retrospective, single arm study design acts as a limitation to the process 
of data collection. Since all the data points were collected through a chart review process 
of the EMR data, abstracting data points required for the purpose of this study was 
dependent on only the existing data in EPIC.  The absence of a valid internal comparator 
group in this study, makes the toxicity and efficacy assessments less tangible. Secondly, 
the relatively shorter duration of follow-up could be attributed to the less mature survival 
curve of this cohort. Additionally, the investigator was unable to follow several patients to 
observe whether they re-started the study treatment after the resolution of symptoms. Third, 
the small sample size is an added challenge in extrapolating results to a larger population 
of patients treated on this combination therapy outside of DFCI. That is, the generalizability 
of the study might be compromised. Also, the exclusion criteria for this study cohort does 
not match the exclusion criteria listed in the check-mate trials. Lastly, the smaller sample 
size makes it difficult to attribute the variations in the toxicity due to the Ipi-Nivo 
combination therapy.  
 
Future direction: 
The results of the study suggest that in future investigations, including a direct 
comparison arm, such as, patients treated with Nivolumab mono or Ipilimumab alone as a 
comparator group for the Ipi-Nivo combination, in the real-world clinical settings would 
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be valuable in yielding further evidence of the nature of toxicity and efficacy of the 
combination therapy. 
A large database (big data) Pharmacoepidemiological study of patients treated with 
the Ipi-Nivo combination will allow us to observe the frequency of incidence of irAEs and 
to detect the causality of the occurrence of irAEs to the combination treatment. Further, 
with a larger database, collection of data points for treatment related irAEs could be more 
detailed, enabling us to study the time to resolution of irAEs, the over-all dose of steroids 
and second line immunosuppressant such as infliximab and mycopheylate mofetil that 
maybe required to reverse the symptoms could be measured, which is an important factor 
for clinical management of irAEs.  
With a larger sample size, stratification by BRAF mutation (BRAF V600 + or BRAF wild 
type) status could be performed which will indicate the observed effect of toxicity and 
efficacy in the two groups.  
Melanoma prognosis for patients with brain metastasis is poor and therefore, the 
rate of survival and the rate of immune-related toxicity in patients with brain metastases 
has not been investigated yet. Data from this study supports the need for a sub-group 
analysis for patients with brain metastasis to compare the intra-cranial objective response 
rate and rate of grade 3-4 toxicity in this population as patients with treated brain metastases 
were included in the DFCI cohort.  
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CONCLUSION 
 
The results of the study show that, at The Dana-Farber Cancer Institute, the 
observed rate of Ipi-Nivo related, grade 3-4 irAEs is 32.6%, which is lower than the 
reported rate in the pivotal phase II and III clinical trials (54.5%) that led to the approval 
of combination therapy.   
The majority of patients in the study exhibited a partial response rate of 50%. The 
median overall survival for this cohort was not reached and 8 deaths were reported during 
the follow up period. None of the deaths were related to the study treatment.  
Furthermore, this study highlights the need for increasing patient and clinician 
awareness of the irAEs for better management of symptoms so that majority of the adverse 
events can be detected at early stages and reversed. Thereby allowing patients to resume 
treatment with check-point inhibitors.  
In conclusion, the study underlines that as newer immuno-oncologic agents will 
continue to enter the clinical, and due to different mechanisms of action, the immune 
system will elicit distinct clinical responses in normal tissues as well. Hence, management 
of adverse events require a multidisciplinary team of health-care professionals and patients 
to ensure that immune-therapeutic agents may not be self-limiting to their efficacy in 
cancer treatment54  
 
 
	50 
APPENDIX 
Appendix 1: treatment received for brain metastasis:  
 
Treatment Received     8 patients with brain metastasis  
Number (n) 
Surgery 2 
Whole brain radiation therapy 1 
Stereotactic radiation surgery(SRS) 2 
Treatment with trametinib+ dabrafenib 
and SRS 
2 
SRS with hyperbaric oxygen  1 	
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Appendix 2: RECIST 1.1 criteria for tumor assessment is as follows: 
Response  Criteria for evaluation of target 
lesions 
Criteria for evaluation of non-target 
lesions 
Complete 
Response 
(CR) 
• Disappearance of all target 
lesions 
• Any pathological lymph nodes 
must have reduction in the 
short axis to <10mm 
• Disappearance of all non-target 
lesions and normalization of 
tumor marker level.  
• All lymph nodes must be non-
pathological in size(<10mm short 
axis) 
Partial 
Response 
(PR) 
• At least a 30% reduction in the 
sum of the diameters of target 
lesions from the baseline 
measurement of the sum of 
diameters   
 
Progressive 
Disease 
(PD) 
• A minimum of 20% increase 
in the sum of diameters of the 
target lesions from the 
reference point of the smallest 
sum of diameter in the study 
(it includes the baseline sum, 
if that is the smallest sum in 
the study) 
• Unequivocal progression of 
existing non-target lesions. 
Unequivocal progression is 
defined as: “on the basis of the 
non- target lesion disease, there 
must be an overall level of 
substantial worsening in the non-
target disease.  
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• The sum of diameters must 
also indicate an absolute 
increase of at least 5.0mm 
• Significant increase in the overall 
tumor burden , necessitating a 
discontinuation of therapy.  
Stable 
Disease 
(SD) 
• Neither significant shrinkage 
or  increase to quantify as PR 
or PD , respectively 
• Non-CR / Non- PD 
• Persistence of more than one non-
target lesion(s) and / or  
• Tumor marker level above the 
normal limits 
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